CD36-mediated uptake of oxidized low-density lipoprotein (oxLDL) plays a pivotal role in macrophage foam-cell formation and atherogenesis. Previously we reported on intermedin (IMD), a novel member of the calcitonin gene-related peptide family, in atherosclerotic plaque reducing atherogenesis in apolipoprotein E-deficient (apoE 2/2 ) mice. Here, we studied the role of IMD in CD36-mediated macrophage foam-cell formation.
Introduction
Atherosclerosis is the leading cause of death in industrialized societies and may soon have this status worldwide. The essential steps of atherosclerosis development are the migration of circulating monocytes into the subendothelial arterial space and their differentiation into macrophages, which leads to rapid uptake of modified LDL and subsequent foam-cell formation. Interfering in foam-cell formation by downregulating the ratio of acyl-coenzyme A to cholesterol acyltransferase-1, inhibiting lipid uptake, and promoting lipid export, for example, affects the progression of atherosclerosis and helps regress atherosclerotic lesions. In the past decades, compelling evidence from in vitro, in vivo, and clinical studies has revealed that endogenous bioactive peptides, such as adiponectin, heregulin-b(1), glucagon-like peptide 1, and salusin-a, respectively, can attenuate the development and progression of atherosclerotic lesions. 1 We and others have previously reported that intermedin (IMD), a novel vasoactive peptide of the calcitonin gene-related peptide (CGRP) superfamily IMD, inhibits vascular calcification in rats and reduces atherosclerotic lesions in apoE 2/2 mice. 2, 3 IMD (also named adrenomedullin 2) was identified in 2004 by two independent research groups using genomic screens. 4, 5 IMD binds non-selectively to both CGRP and adrenomedullin receptors 4 and plays pivotal roles in maintaining cardiovascular function and homoeostasis. However, the underlying mechanism remains elusive. Previously, we showed that IMD repression of scavenger receptor A (SR-A) helped ameliorate foam-cell formation induced by acetylated LDL (acLDL) and atherosclerotic lesions. 3 Of interest, acLDL uptake was predominantly driven by SR-A, whereas uptake of mildly oxidized LDL (oxLDL) was primarily mediated by CD36; both contribute to foam-cell formation. 6 Therefore, more specific functions and mechanisms of IMD in atherogenesis remain to be explored. The uptake of oxLDL occurs via the scavenger receptor CD36; notably, the type B family members play an essential role in foam-cell formation. 6, 7 Deletion of CD36 in hyperlipidaemic mouse models markedly decreased atherosclerosis and arterial lipid accumulation. 8 -10 Agents that decrease CD36 expression can also ameliorate atherogenesis. 11 -13 However, the mechanisms underlying the regulation of CD36 expression, especially whether it is regulated by vasoactive peptides, remain to be elucidated. We investigated the role of IMD in reducing oxLDL-induced macrophage foam-cell formation by affecting CD36 expression in cultured macrophages and apolipoprotein E-deficient (apoE 2/2 ) mice. Here, we provide a novel mechanism of tristetraprolin (TTP)-mediated CD36 mRNA degradation in macrophages. ) (Phoenix Pharmaceuticals, Belmont, CA, USA) for 6 weeks. And then mice were anaesthetized with ketamine/ xylazine before blood and tissue samples were obtained for further analysis.
Methods

Materials
Cell culture
Peritoneal macrophages were isolated as described. 3 Eight-week-old C57BL/6J male mice were injected intraperitoneally with 2 mL 4% thioglycollate broth (BD Biosciences Clontech, CA, USA). Three days later, macrophages were obtained by peritoneal lavage with 8 mL cold phosphatebuffered saline (PBS) with 10 mM EDTA and 10% fetal bovine serum (FBS) after anaesthetized with ketamine/xylazine. Cells were plated at 1.0 × 10 6 per mL RPMI-1640 with 10% FBS. After incubation for 3 h at 378C, 
Analysis of atherosclerotic lesions
The upper portion of the heart and the proximal aorta of apoE 2/2 mice were obtained, embedded in optimal cutting temperature compound (Fisher, Tustin, CA, USA), and stored at 2408C. Serial 6 mm thick cryosections of the aorta, beginning at the aortic sinus, were collected for a distance of 400 mm. Sections were stained with Oil-red O. The Oil-red O-positive areas in digitized colour images of stained aortic sinus sections (three equally spaced sections per mouse; n ¼ 5 per group) were quantified using the Image-Pro Plus 5.02 image analysis software, and the data are expressed as per cent of the total section area. 
Serum IMD and lipids assay
Dil-oxLDL uptake
Macrophages were incubated with Dil-oxLDL (10 mg/mL) for the indicated time at 378C. Fluorescence intensity was examined by a confocal microscopy (Leica, Germany). Images were acquired at identical laser output, gain, and offset.
Immunofluorescence analysis
Treated cells or frozen sections were fixed with 4% paraformaldehyde, permeabilized by incubation in 0.1% Triton X-100 in 5% bovine serum albumin (BSA)-PBS for 15 min, then incubated with primary antibodies against Mac3 (dilution 1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or CD36 (1:200, Abcam, Cambridge, MA, USA) for 1 h at 378C and overnight at 48C. After a washing, cells or tissue were incubated with corresponding secondary antibodies (1:300) for 1 h at 378C. Nuclei were labelled by Hoechst 33342 staining. Negative controls were omission of primary antibody. Three frozen sections (take one section per 100 mm interval) of the aortic sinus per mice (n ¼ 5 mice per group) were used for the analysis of CD36 fluorescence intensity. Fifty Mac3-positive cells within the plaque per section were randomly selected, and the fluorescence intensity of CD36 was quantified by the ImagePro Plus 5.02 image analysis software and the relative density was shown.
LDL preparation and oxidation
LDL was isolated from fresh plasma of healthy subjects as described, 16, 17 then incubated with 5 mM CuSO 4 for 24 h at 378C; Cu 2+ was removed by extensive dialysis with PBS overnight. Oxidation of LDL was confirmed by the measurement of thiobarbituric acid-reactive substance (TBARS) with malonaldehyde bis (dimethyl acetal MDA) as the standard. The protein content was determined by the bicinchoninic acid (BCA) protein assay kit with BSA as the standard. OxLDL containing 20 -50 nM TBARS defined as MDA equivalent per milligram LDL protein was used for further experiments.
Biotin pull-down assays
The synthesis of biotinylated transcripts and analysis of RNA-binding proteins (RBPs) bound to biotinylated RNA were as described. 14 cDNA from RAW264.7 cells was used as a template for PCR amplification of the 5 ′ untranslated region (5 ′ -UTR), the coding region (CR) and the CD36 3 ′ -UTR.
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The 5
′ primers contained the T7 RNA polymerase promoter sequence (T7):
′ were used to prepare the CD36 5 ′ -UTR template (positions 1 -487); (T7) 5
′ -GAGAATGGGCTGTGATCGGAA-3 ′ and 5
′ -GTGTAGGCTCATCCACTACTTA-3 ′ were used to prepare the CR of CD36 (positions 488 -1906); and (T7)5
′ -AAGTAGTGGATGAGCCT-ACAT-3 ′ and 5 ′ -ATCTGATTTTAATGACATCGTTTC-3 ′ were used to prepare the CD36 3 ′ -UTR template (positions 1907 -3566). PCR-amplified products were used as templates to transcribe biotinylated RNAs with T7 RNA polymerase and biotin -cytidine 5 ′ -triphosphate. Biotinylated transcripts (1 mg) were incubated with 120 mg cytoplasmic lysates for 30 min at room temperature. Complexes were isolated with the use of paramagnetic streptavidin-conjugated Dynabeads (Invitrogen, Carlsbad, CA, USA). Isolated protein was used for western blot analysis. Actin was a control for binding specificity.
Ribonucleoprotein immunoprecipitation assays
To assess the association of endogenous TTP and CD36 mRNA levels, immunoprecipitation (IP) of TTP-mRNA complexes was performed as described.
14 Twenty million RAW264.7 cells were collected per sample, and lysates were used for IP for 4 h at room temperature with excess (30 mg) IP antibody (IgG or anti-TTP). RNA in IP materials was used in RT-PCR, then PCR analysis to detect the presence of CD36 mRNA. The forward and reverse PCR primers for mouse CD36 genes were 5 ′ -TCTCCCTGAAGCCAATCT-3 ′ and 5
′ -GTTTTCTCGCCAACTCCC-3 ′ . Western blot analysis, real-time PCR analysis, IP , and CD36 promoter activity assay were described in Supplementary material online.
Statistical analysis
Data are expressed as means + SEM. Student's t-test was used for comparing two groups and one-way ANOVA for multiple groups, followed by Bonferroni's correction as applicable (GraphPad Prism Software; GraphPad). P , 0.05 was considered statistically significant. (300 ng kg 21 h 21 ) by osmotic minipumps for 6 weeks. Saline-and IMDtreated apoE 2/2 mice did not differ in food intake or body weight (see Supplementary material online, Figure S1A and B), or serum cholesterol levels and oxLDL (Table 1) . However, IMD-treated mice showed fewer foam cells in peritoneal macrophages on Oil-red O staining ( Figure 1A) , and significantly reduced intracellular free cholesterol, by 74.0% ( Figure 1B) , and TC, by 40.4% ( Figure 1C ) when compared with salinetreated mice. Furthermore, Dil-oxLDL uptake was significantly decreased in peritoneal macrophages of IMD-treated apoE 2/2 mice ( Figure 1D) . Thus, IMD reduced macrophage foam-cell formation and oxLDL uptake in vivo. Figure S2A and B). These effects were further confirmed by IMD reducing cell TC levels in oxLDL-treated peritoneal macrophages ( Figure 2C ) and RAW264.7 cells ( Figure 2D ). Intracellular free cholesterol, increased by oxLDL (50 mg/mL, 24 h), was also decreased with IMD (20 nM) treatment ( Figure 2E ). Peritoneal macrophages pre-treated with IMD (20 nM) for 24 h showed low Dil-oxLDL (10 mg/mL) uptake at various times (0.5, 1, 2, and 4 h) when compared with the control ( Figure 2F) . Therefore, IMD inhibited oxLDL uptake and foam-cell formation in macrophages in vitro.
IMD reduces CD36 expression in macrophages of apoE 2/2 mice
Because oxLDL-triggered foam-cell formation is mainly mediated by CD36, we investigated whether IMD treatment regulates CD36 expression. In line with our previous study, 3 IMD administered by osmotic Figure 3C ). Protein ( Figure 3D ) and mRNA levels ( Figure 3E ) of CD36 were also decreased in IMD-treated mouse peritoneal macrophages. These results showed that IMD down-regulated CD36 expression in macrophages of apoE 2/2 mice.
IMD reduces CD36 protein and mRNA levels by accelerating CD36 mRNA decay
IMD significantly reduced CD36 protein and mRNA levels over time (4-24 h, Figure 4A and C) and by dose (10-50 nM, Figure 4B and D) in primary macrophages. Thus, IMD has inhibitory effects on CD36 expression at both protein and mRNA levels. CD36 is a target gene of PPARg. 18 However, IMD had no effect on the total or phosphorylated PPARg protein level or its nuclear translocation (see Supplementary material online, Figure S3A and B). IMD (20 nM) did not affect CD36 promoter activity in macrophages ( Figure 4E ). IMD markedly shortened the half-life (t 1/2 ) of CD36 mRNA from 8.98 to 4.07 h when mRNA transcription was inhibited by actinomycin D ( Figure 4F) . Thus, IMD reduced CD36 expression by accelerating CD36 mRNA degradation.
TTP mediates IMD-increased degradation of the CD36 mRNA level
RBPs play important roles in the control of mRNA stability. The CD36 mRNA level was not affected in RAW264.7 cells transiently transfected with plasmids expressing CUGBP1 and AUF1 or transfected with vectors expressing HuR and AUF1 shRNA for 48 h ( Figure 5A and B) . However, levels of CD36 mRNA ( Figure 5A and B) and protein ( Figure 5C and D) were significantly decreased with TTP overexpression and increased with shRNA knockdown of TTP, respectively. As expected, with TTP knockdown in macrophages, IMD could not decrease the levels of CD36 mRNA ( Figure 5E ) or protein ( Figure 5F ). Therefore, TTP is the essential RBP for IMD-increased CD36 mRNA degradation.
IMD increases TTP binding to the 3 ′ -UTR of CD36 mRNA by reducing TTP phosphorylation
Hypophosphorylated TTP binds to the 3 ′ -UTR of mRNA and induces mRNA degradation. 19 Our biotin pull-down assays showed that TTP could bind to the 3 ′ -UTR of CD36 mRNA containing multiple AU-rich elements but not the 5 ′ -UTR or CR ( Figure 6A ). The interaction of intracellular CD36 mRNA with TTP was further confirmed by ribonucleoprotein (RNP) IP assays: RT-PCR confirmed the presence of endogenous CD36 mRNA in anti-TTP immunoprecipitated RNP complexes but absence in the non-specific IgG control ( Figure 6B ). We wondered whether the inhibitory effect of IMD on CD36 expression was due to up-regulation of TTP expression and consequently increased TTP activity. IMD had no effect on TTP mRNA or protein levels (see Supplementary material online, Figure S4 ) but markedly increased TTP binding to CD36 mRNA ( Figure 6B) , which was accompanied by decreased TTP serine phosphorylation in vitro ( Figure 6C ) and in vivo ( Figure 6D) . Therefore, IMD increases TTP binding to the 3 ′ -UTR of CD36 mRNA by inhibiting TTP serine phosphorylation.
Discussion
Lipid-laden macrophage-derived foam cells are the predominant cell type in the formative stages of atherosclerosis. Foam-cell formation through scavenger receptors is generally thought to be a protective mechanism during the initial stages of atherogenesis because of the ability of foam cells to remove potentially harmful lipids. However, the system frequently goes awry when macrophage pathways for metabolizing lipoprotein-derived cholesterol become overwhelmed. 20 Thus, agents reducing the scavenger receptor CD36 have been developed to ameliorate atherosclerosis. 11 -13 Here, we demonstrated that the endogenous vasoactive peptide IMD decreased CD36 mRNA and protein levels by accelerating CD36 mRNA decay, thus resulting in decreased oxLDL uptake, intracellular cholesterol accumulation, and foam-cell formation by macrophages in cultured macrophages and apoE 2/2 mice.
TTP-mediated CD36 mRNA degradation was also identified as a novel mechanism regulating CD36 expression, with IMD accelerating the CD36 mRNA decay and decreasing the CD36 protein level. Thus, the present work provides a potential new pathway targeting CD36 mRNA degradation for treating atherosclerosis and further explores the mechanism of IMD-reduced atherogenesis. The expression of IMD is elevated in the heart of rats with congestive heart failure, and down-regulation of endogenous IMD augments myocardial ischaemic/reperfusion injury in rats, 21 -23 which highlights the importantly protective effect of IMD on the heart. IMD is also a potent vasodilator by increasing cAMP production 4, 5, 24, 25 and continuous IMD infusion reduces blood pressure and improves haemodynamic function in spontaneously hypertensive rats. 26 We and others have reported that IMD inhibits vascular calcification in rats and reduces the number of atherosclerotic lesions in apoE 2/2 mice. 2,3,27 Thus, IMD is an endogenous protective peptide in cardiovascular diseases. Macrophage foam-cell formation is a hallmark in the early stages of atherosclerosis and plays an important role in plaque progression and unstability. 28 Monocytes migrating into the subendothelial space differentiate into macrophages and uptake modified LDL, especially oxLDL, through scavenger receptors. CD36 and SR-A internalize most of the acLDL and oxLDL and are responsible for 75-90% of the uptake of modified lipoproteins by macrophages. 6 So, they are keys to macrophage-derived foam-cell formation. Several studies have demonstrated that deletion of CD36 or SR-A in hyperlipidaemic mouse models markedly decreases atherosclerosis and arterial lipid accumulation. 9,29 -32 Thus, uptake of oxLDL or other modified LDL by CD36 or SR-A may be the major pathways of foam-cell formation in vivo, and lipid uptake by either receptor may be a pro-atherosclerotic event.
Our previous results demonstrated that IMD reduces acLDL-induced foam-cell formation and SR-A expression via a distinct mechanism of increased protein stability of phosphatase and tensin homologue. Thus, downregulation of CD36 and SR-A via two distinctive mechanisms may reveal the underlying mechanisms of the IMD effects on reducing macrophage foam-cell formation and atherogenesis. CD36 is a PPARg target gene, and PPARg-mediated transcriptional regulation is required for its induction. 18 An agent inhibiting PPARg activity, such as pitavastatin, reduces CD36 mRNA and surface protein expression in macrophages. 33 Here, IMD did not change PPARg expression and its activity. IMD had no effect on CD36 promoter activity, so PPARg-mediated transcriptional regulation is not involved in IMD ′ -UTRs of some cytokine mRNAs and promotes their degradation. For example, TTP is a component of a negative feedback loop that interferes with tumour necrosis factor-a (TNF-a) production by destabilizing its mRNA. 34 Our previous study showed that TTP also mediates the effect of TNF-a on the expression of progressive ankylosis protein homologue and vascular calcification. 15 TTP can be directly phosphorylated by p38 and MK-2 at two major sites, Ser52 and Ser178; 35 -37 especially phosphorylation of TTP on Ser178 creates a binding site for 14-3-3 proteins. 37 The complex of phospho-TTP-14-3-3 is prevented from binding ARE sequences on the 3 ′ -UTR of mRNA, thus protecting the mRNA against degradation. 38 Here, we demonstrate that TTP destabilizes CD36 mRNA, and this process is regulated by IMD via reducing TTP phosphorylation, which enhances its binding to CD36 3 ′ -UTR. Of note, sequence analysis with TargetScan Mouse (Release 6.2) predicts several potential microRNA (miRNA)-binding sites within the CD36 mRNA, for example, mmu-miR-669b targets position 86-93 of CD36 3 ′ -UTR). However, we lack direct evidence for regulation of CD36 mRNA by miRNAs, so more experiments are needed to explore this regulation.
Besides having pro-atherogenic effects, macrophage CD36 and/or SR-A are also up-regulated and play a role in insulin resistance and diabetes, 39 -41 as well as atherosclerotic plaque rapture, 42 which suggests potential targets for treating diabetes and preventing plaque rapture by inhibiting CD36 and SR-A. Together with our previous results of IMD decreasing SR-A and reducing atherosclerosis, 3 the present finding that IMD also reduces CD36 expression may have important clinical implications for preventing and treating atherosclerosis and diabetes.
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Supplementary material is available at Cardiovascular Research online.
